A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.
Also called NCT02630706
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 506 participants
- Sponsor
- Registry
-
NCT02630706
-
- Other papers using this trial's data
- Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02630706. Randomized; double masking; primary purpose treatment. Start 2015-12-16 (actual); primary completion 2017-12-27 (actual). Results posted on 2018-12-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Ertugliflozin 15 mg
- Intervention (Drug)
- Placebo matching ertugliflozin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct02630706- Content hash
b75da482a3b77aa27ae16ffebbdb6b78c6f75034fa9e36fc4c119cd31a4bdd44